Suppr超能文献

系统评价随机临床试验的成本和资源利用情况显示出缺乏透明和全面的数据。

Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data.

机构信息

Department of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University of Basel and University Hospital Basel, Switzerland.

Clinical Trial Unit, Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland.

出版信息

J Clin Epidemiol. 2018 Apr;96:1-11. doi: 10.1016/j.jclinepi.2017.12.018. Epub 2017 Dec 27.

Abstract

OBJECTIVES

Randomized clinical trials (RCTs) are costly. We aimed to provide a systematic overview of the available evidence on resource use and costs for RCTs to support budget planning.

STUDY DESIGN AND SETTING

We systematically searched MEDLINE, EMBASE, and HealthSTAR from inception until November 30, 2016 without language restrictions. We included any publication reporting empirical data on resource use and costs of RCTs and categorized them depending on whether they reported (i) resource and costs of all aspects at all study stages of an RCT (including conception, planning, preparation, conduct, and all tasks after the last patient has completed the RCT); (ii) on several aspects, (iii) on a single aspect (e.g., recruitment); or (iv) on overall costs for RCTs. Median costs of different recruitment strategies were calculated. Other results (e.g., overall costs) were listed descriptively. All cost data were converted into USD 2017.

RESULTS

A total of 56 articles that reported on cost or resource use of RCTs were included. None of the articles provided empirical resource use and cost data for all aspects of an entire RCT. Eight articles presented resource use and cost data on several aspects (e.g., aggregated cost data of different drug development phases, site-specific costs, selected cost components). Thirty-five articles assessed costs of one specific aspect of an RCT (i.e., 30 on recruitment; five others). The median costs per recruited patient were USD 409 (range: USD 41-6,990). Overall costs of an RCT, as provided in 16 articles, ranged from USD 43-103,254 per patient, and USD 0.2-611.5 Mio per RCT but the methodology of gathering these overall estimates remained unclear in 12 out of 16 articles (75%).

CONCLUSION

The usefulness of the available empirical evidence on resource use and costs of RCTs is limited. Transparent and comprehensive resource use and cost data are urgently needed to support budget planning for RCTs and help improve sustainability.

摘要

目的

随机临床试验(RCT)成本高昂。本研究旨在系统综述 RCT 资源利用和成本的现有证据,为预算规划提供支持。

研究设计和设置

我们系统检索了 MEDLINE、EMBASE 和 HealthSTAR 数据库,检索时间从建库至 2016 年 11 月 30 日,无语言限制。我们纳入了所有报告 RCT 资源利用和成本的实证数据的出版物,并根据其报告内容进行分类,具体分类如下:(i)报告 RCT 所有研究阶段(包括构思、计划、准备、实施以及最后一名患者完成 RCT 后的所有任务)的所有方面的资源和成本;(ii)报告若干方面的资源和成本;(iii)报告单个方面(如招募)的资源和成本;或(iv)报告 RCT 的总费用。计算了不同招募策略的中位成本。其他结果(如总费用)则进行描述性列出。所有成本数据均转换为 2017 年美元。

结果

共纳入 56 篇报告 RCT 成本或资源利用的文章。没有一篇文章提供了整个 RCT 所有方面的经验性资源利用和成本数据。8 篇文章报告了若干方面的资源利用和成本数据(例如,不同药物研发阶段的汇总成本数据、特定地点的成本、选定的成本构成部分)。35 篇文章评估了 RCT 一个特定方面的成本(即 30 篇关于招募,其他 5 篇)。每招募一名患者的中位成本为 409 美元(范围:41-6990 美元)。16 篇文章中提供了 RCT 的总费用,每位患者的费用范围为 43-103254 美元,每 RCT 的费用范围为 0.2-6115 百万美元,但在 16 篇文章中的 12 篇(75%)中,收集这些总估计值的方法仍不清楚。

结论

目前 RCT 资源利用和成本的实证证据的有用性有限。迫切需要透明和全面的资源利用和成本数据,以支持 RCT 的预算规划,并有助于提高可持续性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验